CompletedPhase 1/2

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

United States77 participantsStarted 2014-05

Plain-language summary

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 * Open angle glaucoma or Ocular Hypertension Exclusion Criteria: * uncontrolled medical conditions * wearing of contact lenses

What they're measuring

Intra-ocular pressure

Timeframe: 12 weeks

Trial details

NCT IDNCT02129673

SponsorViSci Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-05

View on ClinicalTrials.gov More Open Angle Glaucoma trials